Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Entrada Therapeutics (TRDA) Gross Profit: 2023-2025

Historic Gross Profit for Entrada Therapeutics (TRDA) over the last 3 years, with Sep 2025 value amounting to $1.6 million.

  • Entrada Therapeutics' Gross Profit fell 91.75% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.5 million, marking a year-over-year decrease of 71.42%. This contributed to the annual value of $210.8 million for FY2024, which is 63.38% up from last year.
  • According to the latest figures from Q3 2025, Entrada Therapeutics' Gross Profit is $1.6 million, which was down 17.23% from $1.9 million recorded in Q2 2025.
  • In the past 5 years, Entrada Therapeutics' Gross Profit ranged from a high of $94.7 million in Q2 2024 and a low of $1.6 million during Q3 2025.
  • Over the past 3 years, Entrada Therapeutics' median Gross Profit value was $25.3 million (recorded in 2023), while the average stood at $33.1 million.
  • Its Gross Profit has fluctuated over the past 5 years, first spiked by 421.16% in 2024, then crashed by 97.94% in 2025.
  • Quarterly analysis of 3 years shows Entrada Therapeutics' Gross Profit stood at $41.8 million in 2023, then decreased by 10.63% to $37.4 million in 2024, then slumped by 91.75% to $1.6 million in 2025.
  • Its Gross Profit stands at $1.6 million for Q3 2025, versus $1.9 million for Q2 2025 and $20.6 million for Q1 2025.